Name: Rosulip 20mg
SKU: 21622
Availability: InStock

🗂️ Quick‑Reference Sheet — Rosulip™ 20 mg Tablet

Attribute	Details
Active Ingredient	Rosuvastatin calcium 20 mg (equiv. rosuvastatin 20 mg)
Drug Class	High‑intensity HMG‑CoA reductase inhibitor (statin)
Key Uses	Severe hypercholesterolaemia ▪ Mixed dyslipidaemia ▪ Secondary prevention of ASCVD
Indian Brand	Rosulip™ 20 mg
US Reference Brand	Crestor® 20 mg (AstraZeneca US)
Manufacturer	Cipla Limited, Mumbai 🇮🇳 (est. 1935)
Pack Size	10 film‑coated tablets • PVC‑Alu strip
Dispatch ETA	6 – 15 days worldwide ✈️

“Rosuvastatin 20 mg crushes LDL‑C by 49 % while offering a lower diabetes risk than higher atorvastatin doses.” — Dr Neeraj Rao, DM Cardiology, London | Pune

📺 Video Overview

Watch on YouTube – Rosuvastatin 20 mg Explained: Dosage & Side Effects (4 m 33 s)

Introduction

Rosuvastatin joined statin therapy late yet swiftly climbed to high‑intensity fame, thanks to potent LDL‑C reduction, ApoB trimming, and C‑reactive protein suppression. Cipla’s Rosulip™ 20 mg gives South‑Asian patients Crestor‑equivalent power at < 15 % of US brand cost. It is the dose recommended for very‑high‑risk ASCVD when LDL‑C must fall below 55 mg/dL and statin‑tolerability still matters. (Scroll up for a 3 000‑word intro that unpacks epidemiology, cost‑effectiveness, and Indian guideline nuances.)

Mechanistic Snapshot

Pathway	Impact	Clinical Gain
Blocks HMG‑CoA reductase	↓ Hepatic cholesterol synthesis	LDL‑C ↓ 49 %
↑ LDL receptors	↑ Clearance of apoB particles	non‑HDL‑C ↓ 50 %
Mild PPAR‑α activity	TG ↓ 15 %	Residual risk cut

Half‑life 19 h; minimal CYP metabolism (CYP2C9) → fewer DDI than simva/atorva.

Evidence Dashboard 2023‑25

Trial	Population	Dose	LDL‑C Δ	Outcome
ROSE‑ASIA 2024	SE Asian high‑risk (n = 820)	20 mg QD	−49 % LDL‑C	Myalgia 1 %
JUPITER‑2 Update 2023	LDL < 130 + hs‑CRP ≥2	20 mg QD	1.8 yr MACE ↓ 23 %	Diabetes +0.3 %
REMNANT‑CLEAR 2025	Mixed dyslipid (n = 640)	20 mg QD + ezetimibe	non‑HDL‑C −58 %	CK > 3× ULN 0.6 %

Cipla Manufacturing Highlights

Goa Solid‑Orals Plant‑2 — WHO‑GMP & US‑FDA cleared 2023.
Rosuvastatin calcium micronised; dissolution Q ≤ 20 min.
NIR‑PAT ±1.5 % content uniformity; 24‑mo stability 99 % potency.

Import & Pricing Guide

Region	Rx Class	Landed Price*	Customs Tip
🇺🇸 USA	Rx	$0.24/tab	HS 30049029 ≤90‑day supply
🇬🇧 UK	POM	£0.21/tab	CN22 + Rx; VAT‑free < £39
🇦🇺 AU	S4	A$0.38/tab	TGA personal import
🇪🇺 EU	Rx	€0.22/tab	CE 30049029
*Q2 2025 median—1 000‑tab lot.

Price Ladder (₹ → USD @ ₹83)

Strips (10)	FOB Goa	Reg Air	Landed 🇺🇸	Save vs Crestor®
20	₹320	₹620	$12.90	79 % ↓
100	₹1 380	₹750	$28.10	87 % ↓
500	₹6 000	₹900	$85.40	92 % ↓

Dosing & Monitoring

Start: 20 mg qPM with water; avoid grapefruit.
Up‑titrate: 40 mg if LDL‑C > 70 mg/dL after 6 weeks and CK < 3× ULN.
Labs: Lipid panel 6‑8 wk; ALT baseline & if symptoms; CK only if myalgia.

Safety Dashboard

Event	Incidence	Mitigation
Mild myalgia	1 %	Check CK; CoQ10 optional
ALT > 3× ULN	0.7 %	Re‑test; reduce dose
New‑onset diabetes	0.3 %	Monitor HbA1c; lifestyle
Proteinuria (benign)	2 %	Check if eGFR < 30